Kyverna appoints Warner Biddle CEO, Christi Shaw to board; Maag resigns

Kyverna Therapeutics, Inc.

Warner Biddle appointed CEO and Class III director, effective Sept 16; previously SVP Global Head of Commercial at Kite Pharma.
Biddle receives 2,579,259-share option (4-year vest, 1-yr cliff), $625K salary, $650K sign-on bonus, and up to $150K relocation.
Peter Maag, Ph.D. resigned as CEO and director Sept 13; will provide contractor services for up to 6 mo at $45,833/mo plus $550K severance.
Christi Shaw appointed Class II director; granted option for $350K in shares vesting over 36 months; succeeded Brian Kotzin, who resigned.
Company adopted 2024 Inducement Equity Incentive Plan reserving 4M shares for new-hire equity grants, used for Biddle's option.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Warner Biddle

Chief Executive Officer and Class III director

KYTX · Kyverna Therapeutics, Inc.

Effective: 2024-09-16
Filed: September 16, 2024, 7:59 PM ET

appointed Warner Biddle as the Company’s Chief Executive Officer and as a Class III director of the Company, in each case effective September 16, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Warner Biddle was appointed as Chief Executive Officer and Class III director at Kyverna Therapeutics, Inc..

Action: appointed
Role: Chief Executive Officer and Class III director

Exact text from the filing

appointed Warner Biddle as the Company’s Chief Executive Officer and as a Class III director of the Company, in each case effective September 16, 2024

View on SEC.gov

Kyverna Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-078736

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.